Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246504 | 1.00 | PTPN11 (0.34) | PTPN11KCNH2SLC2A1KDM4EGAA | |
| SCHEMBL3253088 | 1.00 | PTPN11 (0.34) | PTPN11KCNH2SLC2A1KDM4EGAA | |
| SCHEMBL3253090 | 1.00 | PTPN11 (0.34) | PTPN11KCNH2SLC2A1KDM4EGAA | |
| SCHEMBL6079988 | 0.78 | CYP19A1 (0.45) | KCNH2SLC2A1SSTR2 | |
| SCHEMBL6080374 | 0.78 | SSTR2 (0.37) | PTPN11KCNH2SLC2A1SSTR2 | |
| SCHEMBL6080089 | 0.77 | SSTR2 (0.44) | KCNH2SLC2A1SSTR2 | |
| SCHEMBL13356503 | 0.77 | KCNH2 (0.46) | KCNH2SLC2A1 | |
| SCHEMBL5744836 | 0.76 | SSTR2 (0.48) | KCNH2SLC2A1SSTR2 | |
| SCHEMBL5657153 | 0.76 | KCNH2 (0.46) | KCNH2SLC2A1 | |
| SCHEMBL5747963 | 0.76 | SLC2A1 (0.46) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | PTPN11 4239/4885KCNH2 1182/4885SLC2A1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.